Fulcrum Therapeutics, Inc. Common Stock (FULC)
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address genetically defined diseases. The company leverages its gene control platform to identify and develop treatments aimed at restoring or modulating gene expression to improve patient outcomes.
Company News
Fulcrum Therapeutics granted 35,000 non-statutory stock options to a new employee at $7.27 per share, with a ten-year term and four-year vesting schedule.
Biohaven's pipeline candidate, troriluzole, met the primary endpoint in a pivotal study for the treatment of spinocerebellar ataxia, a rare neurological disease. The study showed a 50-70% delay in disease progression compared to untreated patients.
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
These recent winners still have a long way to run.